#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Hav­ing worked in par­al­lel for years to move their re­spec­tive PD-1 in­hibitors up to the first-line treat­ment of gas­troin­testi­nal can­cers, Mer­ck and Bris­tol My­ers Squibb …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER